EY launched its M&A Firepower report, showing that life sciences mergers and acquisitions (M&A) activity in 2018 totaled $198 billion USD. According to the report, life sciences companies focused on building therapeutic scale and optimizing their portfolios, and the 2018 market conditions-especially high valuations for target acquisitions-drove dealmaking away from megamergers toward bolt-on acquisitions and divestitures.
Additionally, the uncertain return on investment and the rapid pace of technology change mean life sciences companies will likely prioritize digital alliances in favor of M&A in 2019.
Key findings highlighted in this year’s M&A Firepower report include:
The report identifies a number of key industry trends likely to drive M&A in 2019 and beyond:
Read the full report here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.